goralatide has been researched along with Kidney Failure, Chronic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujioka, K; Fujioka, T; Itoh, H; Katagiri, F; Mimata, H; Sato, F; Sato, Y; Suzuki, Y | 2 |
| Azizi, M; Ezan, E; Gerineau, V; Ménard, J; Reny, JL; Wdzieczak-Bakala, J | 1 |
| Aldigier, JC; Comte, L; Le Meur, Y; Leroux-Robert, C; Lorgeot, V; Praloran, V; Szelag, JC | 1 |
| Macdougall, IC | 1 |
| Abu-Alfa, AK; Perazella, MA | 1 |
2 trial(s) available for goralatide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Significant decrease in plasma N-acetyl-seryl-aspartyl-lysyl-proline level in patients with end stage renal disease after kidney transplantation.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Female; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Oligopeptides; Regression Analysis; Transplantation, Homologous | 2014 |
Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Captopril; Humans; Kidney; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Oligopeptides; Peptidyl-Dipeptidase A | 1999 |
4 other study(ies) available for goralatide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Clinical Implications of Plasma N-acetyl-seryl-aspartyl-lysyl-proline Level in Stable Kidney Transplant Recipients.
Topics: Adolescent; Adult; Aged; Anemia; Angiotensin II; Biomarkers; Creatinine; Erythropoietin; Humans; Kidney Failure, Chronic; Kidney Transplantation; Middle Aged; Oligopeptides; Postoperative Complications; Prolyl Oligopeptidases; Serine Endopeptidases; Young Adult | 2016 |
Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Cell Count; C-Reactive Protein; Case-Control Studies; Drug Administration Schedule; Erythropoietin; Ferritins; Half-Life; Hemoglobin A; Humans; Kidney Failure, Chronic; Linear Models; Oligopeptides; Parathyroid Hormone; Recombinant Proteins; Renal Dialysis | 2001 |
Ace inhibitors and erythropoietin responsiveness.
Topics: Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Drug Interactions; Erythropoiesis; Erythropoietin; Humans; Insulin-Like Growth Factor I; Kidney Failure, Chronic; Oligopeptides; Recombinant Proteins | 2001 |
Angiotensin-converting enzyme inhibitors and anemia in chronic kidney disease: a complex interaction.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Erythropoiesis; Erythropoietin; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Oligopeptides | 2002 |